Back to overview
Jelle Wesseling group
Jelle Wesseling is consultant breast pathologist. He became
Master of Science (MSc) in Medicine in 1987 and cum laude MSc in
chemistry focusing on molecular and cell biology in 1991, both at
the University of Groningen, the Netherlands. He received his PhD
at the Netherlands Cancer Institute in 1997 under supervision of
Prof. Dr. Piet Borst, Prof. Dr. Carl Figdor, and Dr. John Hilkens
about the role of the carcinoma-associated mucin episialin (MUC1,
CD227, EMA, CA15-3 antigen) in cell adhesion and tumor progression.
He obtained his MD cum laude at the Free University in Amsterdam in
1999. He was trained as a pathologist at the University Medical
Center Groningen for which he was registered in 2004. He returned
to the NKI in 2006 where he became a consultant breast pathologist
and group leader. He is member of various breast cancer working
committees, both in the Netherlands as well as in Europe.
His research focuses on optimizing personalized diagnosis and
treatment of each breast cancer patient by searching for novel
prognostic and predictive biomarkers using a combination of
pathology, molecular analyses, and epidemiology. Ultimately, he
aims at answering the questions which breast cancer patient needs
what type of treatment for how much benefit.